Chromic Phosphate P 32
Pronunciation: KROME-ik FOSS-fate
Phosphocol P 32
- Suspension 15 mCi with a concentration of up to 5 mCi/mL
Local irradiation by beta emission. Chromic phosphate P32 decays by beta emission with a physical half-life of 14.3 days.
Indications and UsageAdults
Treatment of peritoneal or pleural effusions caused by metastatic disease, cancer.
Presence of ulcerative tumors; administration in exposed cavities or where there is evidence of loculation unless its extent is determined.
Dosage and AdministrationTreatment of Peritoneal or Pleural Effusions Caused by Metastatic Disease, Cancer
Adults (about 70 kg)
Intraperitoneal 10 to 20 mCi.Adults (about 70 kg)
Intrapleural 6 to 12 mCi.Adults (about 70 kg)
Interstitial 0.1 to 0.5 mCi/g of estimated weight of tumor.
- Consult manufacturer product information for specific calibration and dosimetry information.
- For interstitial or intracavitary use only. Measure dose by suitable radioactivity calibration system immediately prior to use.
None well documented.
Laboratory Test Interactions
None well documented.
Nausea; abdominal cramping.
Transitory radiation sickness; bone marrow depression; pleuritis; peritonitis.
Category C .
Use only when clearly needed.
This product contains benzyl alcohol, which has been associated with fatal “gasping syndrome” in preterm infants.
Careful intracavitary instillation is required to avoid placing the dose of chromic phosphate P 32 into intrapleural or intraperitoneal loculations, bowel lumen, or the body wall. Intestinal fibrosis or necrosis and chronic fibrosis or the body wall have resulted from unrecognized misplacement of the therapeutic agent.
Not for intravascular use.
Large tumor masses
When other forms of treatment fail to control effusion, chromic phosphate P 32 may be used.
Ensure minimum radiation exposure to the patient and occupational workers consistent with proper patient management.
- Advise patient, family, or caregiver that medication will be prepared and administered by health care provider in a health care setting.
- Advise patient, family, or caregiver that medication may be used in combination with other agents to achieve maximum benefit possible.
- Advise patient, family, or caregiver that medication is usually administered one time only.
- Advise patient, family, or caregiver to immediately report any of the following to health care provider: difficulty breathing or severe chest pain caused by breathing; fever, chills or other signs of infection; sores in mouth; unusual bleeding or bruising.
- Advise patient, family, or caregiver to report any of the following to health care provider: persistent nausea or vomiting or appetite loss; any other unexplained sensation.
Copyright © 2009 Wolters Kluwer Health.